GENERAL10 Sept 2026
'Buy' Nephrocare Health Services for 16% upside, says ICICI Securities; check share price target | Stock Market News
ICICI Securities has upgraded Nephrocare Health Services to a 'buy' from 'add' and raised its target price to ₹825 from ₹725 earlier. The dialysis company's shares have risen 64% this year, even as the Sensex fell 12%. The brokerage expects strong growth from its asset-light model and overseas centres. Investors holding or watching this stock should treat the call as one view, not a guarantee.
Key Statutory Highlights
- ICICI Securities upgraded Nephrocare Health Services to a 'buy' from 'add' and raised its target price to ₹825 from ₹725 earlier.
- Nephrocare shares have gained 64% year-to-date, while the Sensex fell 12%, and the stock closed 1.94% higher at ₹747.35 on the BSE on 10 September.
- The brokerage expects Nephrocare's revenue, EBITDA and PAT to grow at CAGRs of about 21.7%, 27.6% and 43.4% over FY26–29E.
Actionable Advice for Taxpayers / Founders:If you hold or are considering this stock, read the full ICICI Securities report and check it against your own goals and risk comfort. A brokerage upgrade is an opinion, not a promise of returns.
Statutory Disclaimer: TaxQue Shorts are AI-assisted editorial briefs for compliance awareness. This brief has not passed every source check; confirm the original notification before acting. This does not constitute formal legal or CA counsel.
TaxQue News Desk
Share: